Education
About Us
Working with TipRanks
Follow Us
Rein Therapeutics (RNTX)
NASDAQ:RNTX
RNTX Stock Chart & Stats
$1.26
--
Market closed
$1.26
--
Day’s Range― - ―
52-Week Range$1.02 - $2.96
Previous CloseN/A
VolumeN/A
Average Volume (3M)228.95K
Market Cap
$30.23M
Enterprise Value$25.13M
Total Cash (Recent Filing)$4.05M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Apr 06, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding26,286,383
10 Day Avg. Volume262,542
30 Day Avg. Volume228,948
Financial Highlights & Ratios
PEG Ratio-0.25
Price to Book (P/B)0.76
Price to Sales (P/S)0.00
P/FCF Ratio-1.85
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.41
Forecast
1Y Price Target
$10.00Price Target Upside693.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtEssentially zero debt materially lowers refinancing and interest rate risk over the next 2-6 months, preserving optionality for trial funding and strategic moves. This structural conservatism improves survival odds during clinical development compared with highly leveraged peers.
Regulatory Clearance To Resume Phase 2Lifting the clinical hold is a durable operational inflection: it removes a regulatory barrier, enables U.S. enrollment at ~20 sites, and preserves the program's timeline toward topline data in Q3 2026. This materially improves the pipeline's realistic path to value creation.
Access To Alternative FinancingAbility to raise capital via exempt private note offerings shows the company can secure non-dilutive or flexible funding channels without public equity issuance. Structurally this can extend runway and reduce reliance on volatile public equity markets during clinical development.
Bears Say
Zero RevenueNo commercial revenue is a sustained structural constraint: the business is entirely dependent on external financing and clinical success to ever reach profitability. This leaves cash runway and financing access as primary determinants of long-term viability.
Persistent Negative Operating And Free Cash FlowOngoing multi-period cash burn erodes liquidity and forces repeated capital raises or cost cuts. Structurally worsening FCF magnifies dilution risk, limits ability to fund trials internally, and makes long-term planning contingent on external capital markets or partners.
Erosion Of Shareholders' Equity And Negative ROEDeclining book equity and negative ROE indicate accumulated losses are depleting the balance-sheet buffer that protects creditors and funds operations. Over months, this heightens the chance of dilutive financing and reduces strategic flexibility for pipeline advancement.
Rein Therapeutics News
RNTX FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was $1.02 and its highest was $2.96 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is $30.23M.
When is Rein Therapeutics’s upcoming earnings report date?
Rein Therapeutics’s upcoming earnings report date is Apr 06, 2026 which is in 45 days.
How were Rein Therapeutics’s earnings last quarter?
Rein Therapeutics released its earnings results on Nov 14, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.24 by $0.03.
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate is -0.22.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 26,286,383 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Rein Therapeutics reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.24. Following the earnings report the stock price went down -7.407%.
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in RNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rein Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (693.65% Upside)
$10.00 (693.65% Upside)
Insider Transactions
Bought Shares
Worth $550.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.80%
12-Months-Change
Fundamentals
Return on Equity
-83.28%
Trailing 12-Months
Asset Growth
-48.47%
Trailing 12-Months
Company Description
Rein Therapeutics
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
RNTX Stock 12 Month Forecast
Average Price Target
$10.00
▲(693.65% Upside)
Technical Analysis
―
Kezar Life Sciences
―
Vivos Therapeutics
―
OnKure Therapeutics
―
Rani Therapeutics Holdings
―
Ownership Overview
7.15% Insiders
3.57% Mutual Funds
0.22% Other Institutional Investors
84.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---